ArticleFrontiers in molecular biosciences2025
A novel prognostic model based on epithelial cell progression genes identifies OAS1 as a suppressor of bladder cancer aggressiveness.
Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bladder cancer (BLCA) is a highly heterogeneous malignancy with an unpredictable prognosis. Tumour progression is closely linked to the complex tumour microenvironment (TME), particularly the role of epithelial cells. This study aims to identify key epithelial cell-derived signature genes driving tumour progression, construct a reliable prognostic model, and further explore the biological functions of a pivotal gene, Methods: Single-cell RNA sequencing (scRNA-seq) data from public cohorts were analyzed to identify epithelial cell subpopulations and delineate their malignant progression trajectory. Genes significantly associated with this progression were identified through pseudotime analysis. Bulk RNA-seq and clinical data from The Cancer Genome Atlas (TCGA) BLCA cohort were utilized for least absolute shrinkage and selection operator (LASSO) Cox regression to build a prognostic risk model. The model's predictive efficacy was validated in an independent Gene Expression Omnibus (GEO) cohort. Furthermore, Results: scRNA-seq analysis revealed a distinct epithelial cell subpopulation with high tumor-suppressive activity. A four-gene signature associated with tumor progression was successfully constructed into a prognostic model. Patients in the high-risk group exhibited significantly poorer overall survival in both the TCGA and validation cohorts. Multivariate Cox analysis confirmed the model as an independent prognostic factor. The risk score was significantly correlated with immune infiltration patterns and response to immunotherapy. Among the signature genes, Conclusion: We established a novel prognostic model for BLCA based on epithelial cell tumor progression-associated genes, which serves as a robust predictor for patient outcomes and immunotherapeutic responsiveness. Our findings further highlight
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.